Flu activity ‘elevated’ in US but showing signs of abating, CDC data shows
(PonyWang/Getty Images)
(NEW YORK) — Flu activity remains “elevated” in the United States but is starting to show signs of abating, according to new federal data published Friday.
The 2024-25 flu season was classified by the Centers for Disease Control and Prevention (CDC) as a “high” severity season overall and for all age groups, making it the first high severity season since 2017-2018.
During the week ending Feb. 15, 6.8% of visits to doctors’ offices were for flu-like illness, down from 7.7% of visits over the previous two weeks, CDC data shows.
Emergency department visits for flu also fell to 6.4% during the week ending Feb. 15 from more than 8% for the two weeks prior.
Additionally, 26.9% of tests came back positive for flu during the week ending Feb. 15. This is higher than the peak of 18.2% last flu season but lower than the 31.4% recorded over the previous two weeks.
The CDC estimates there have been at least 33 million illnesses, 430,000 hospitalizations and 19,000 deaths from flu so far this season
At least 86 pediatric flu deaths have been recorded so far, with 18 reported the week ending Feb. 15.
It comes as overall respiratory illness activity is listed as “high” nationwide, CDC data shows.
As of Friday, nine states are listed as having “very high” levels of respiratory virus activity and 14 states are listed as “high.” The remaining states are listed as having “moderate” or “low” levels.
Comparatively, 12 states were listed as “very high” and 20 states were listed as “high” last week.
Meanwhile, although COVID-19 activity is “elevated” in many areas of the U.S., CDC data shows emergency department visits are at low levels and the number of laboratory tests coming back positive is stable.
Respiratory syncytial virus activity was also described as “elevated” but declining in most areas of the U.S., according to the CDC.
Public health experts have recommended children and adults receive the flu and COVID vaccine as well as older adults receive the RSV vaccine, but coverage is “low,” according to the CDC.
As of Feb 8, only 45.3% of adults were vaccinated against the flu and 23,1% were vaccinated with the updated 2024-25 COVID-19 vaccine. Additionally, just 46.7% of adults ages 75 and older have received the RSV vaccine, according to CDC data.
Nearly half of all children are vaccinated against the flu at 45.8%, but just 12.1% have received the updated COVID-19 vaccine.
(NEW YORK) — Moderna has been awarded approximately $590 million from the federal government to help speed up the development of an mRNA-based bird flu vaccine, alongside other influenza vaccines, health officials announced Friday.
The U.S. Department of Health and Human Services (HHS) said in a press release that the funding will allow the pharmaceutical company to accelerate the development of an H5N1 mRNA influenza vaccine “that is well matched to strains currently circulating in cows and birds and expands the clinical data supporting the use of mRNA vaccines that may be needed if other influenza strains emerge with pandemic potential.”
Moderna said the funding will support the expansion of clinical studies “for up to five additional subtypes of pandemic influenza.”
The U.S. government previously awarded the vaccine manufacturer $176 million in July 2024 to help expedite the development of an mRNA vaccine that could be used for bird flu.
mRNA technology is the same type that was used in the development of some COVID-19 vaccines. While some vaccines use a weakened or inactive virus to stimulate an immune response, mRNA vaccines teach the body how to make proteins that can trigger an immune response and fight off an infection.
Researchers can often design mRNA vaccines more quickly than they can produce the live or weakened pathogens needed for a live-attenuated or inactivated vaccine.
The federal government already has two bird flu vaccine candidates, which use traditional vaccine technology, available in the nation’s stockpile. Officials previously noted they’d have 10 million ready-to-use doses within the beginning of 2025. Vaccines were being stockpiled as a precaution.
“Avian flu variants have proven to be particularly unpredictable and dangerous to humans in the past. That is why this response has been a top priority for the Biden-Harris Administration and HHS,” HHS Secretary Xavier Becerra said in a statement on Friday. “Accelerating the development of new vaccines will allow us to stay ahead and ensure that Americans have the tools they need to stay safe.”
Bird flu cases in humans have been spreading across the country since April 2024 with 67 confirmed cases as of Friday, according to the Centers for Disease Control and Prevention (CDC).
The first death of a human bird flu patient was reported in Louisiana earlier this month. The patient was over the age of 65 and had underlying medical conditions, according to health officials.
Most human cases have occurred after coming into contact with infected cattle, infected poultry farms or other culling operations.
The CDC and other public health officials say there is currently no evidence of human-to-human transmission and the risk to the general public is low.
ABC News’ Mary Kekatos contributed to this report.
Human Bird Flu Cases in the U.S. as of January 6, 2025. Image by ABC News. Data via CDC.
(NEW YORK) — In the nearly nine months since the first human case of bird flu was detected in the United States, the virus has continued to spread.
The outbreak infected hundreds of herds and millions of birds before it spread to humans. As of Jan. 6, there have been 66 human cases of bird flu reported in 10 states, according to data from the Centers for Disease Control and Prevention (CDC).
Almost all confirmed cases involve direct contact with infected cattle or infected livestock.
On Tuesday, the first death of a human bird flu patient was reported in Louisiana. The patient was over the age of 65 and had underlying medical conditions, according to health officials.
The CDC says there is currently no evidence of human-to-human transmission and the risk to the general public is low.
However, public health experts say they are worried the virus could mutate and become more transmissible, amplifying the need to ramp up testing and to stockpile vaccines.
Dr. Tony Moody, a professor of pediatrics and infectious diseases specialist at Duke University, said the fact that cases have yet to pass from human to human is “both reassuring, but not completely reassuring.”
He told ABC News, “What we’re concerned about is that, eventually, we might get a variation of this strain that could pass from person to person. That’s really what we’re going to need to see, I think, to get substantial human cases and the potential for a new pandemic strain.”
He added, “So, in terms of peering into the crystal ball for 2025…I think the concern is whether or not we’re going to see something change that will turn it into a pandemic strain that could then really be a problem,” he added.
Fears of mutation or a combination virus
One fear experts have is that the virus will continue to mutate in a way that will cause more human-to-human transmissibility. The experts say that every new human case of bird flu allows the virus an opportunity to mutate.
Recent CDC data found mutations in samples of bird flu collected from the Louisiana patient. What’s more, the mutations were not found in poultry samples collected on the patient’s property, suggesting the changes appeared after the patient became infected.
Moody said that because the virus has not yet mutated in a way to spread more easily between humans, he’s not sure if or when it will happen.
“Given the number of cows that have been infected, the number of birds that have been infected and the fact that the virus essentially mutates every time it replicates, I’m kind of surprised that the mutations that they’re talking about haven’t happened yet,” he said. “So, I actually think there’s a bigger barrier to it becoming a real problem.”
Dr. Peter Hotez, co-director of the Texas Children’s Hospital Center for Vaccine Development and dean of the National School of Tropical Medicine at Baylor College of Medicine, said he believes there is a more likely scenario of the virus becoming more transmissible: an individual getting infected with bird flu and seasonal influenza at the same time.
He said this could lead to the virus “reassorting” to produce a hybrid, or recombinant, virus that could then transmit more easily from person to person.
“Everyone’s focusing on the potential for mutation; that is a serious concern for some,” he told ABC News. “The greater probability is that there could be a reassortment, what could ignite the pandemic or an epidemic.”
The experts say there is no evidence the virus is currently heading towards an epidemic or pandemic, but there has already been one case of severe disease.
Different genotypes, or genetic makeup of the virus, means there could more severe cases.
“What we’ve seen with [bird flu] in the United States is that the particular genotype that’s associated with dairy cows has primarily caused more mild disease in people,” Dr. Meghan Davis, an associate professor of environmental health and engineering at Johns Hopkins Bloomberg School of Public Health, told ABC News.
“What we’ve seen with the case in Louisiana … is caused by a different genotype, one that has been circulating in the wild birds, and these are much more severe cases,” she continued. “This highlights the ability of avian influenzas to cause a wide variety of disease … and I think it is possible that we’re going to see that moving forward.”
Making testing more available
The U.S. has begun ramping up testing with the U.S. Department of Agriculture issuing a federal order for raw milk samples nationwide to be collected and tested and the Food and Drug Administration announcing it is collecting samples of aged raw cow’s milk cheese to be tested.
However, for 2025, Hotez said he believes testing needs to be made more readily available to physicians, especially during flu season.
He said there are likely cases of bird flu going undiagnosed, and testing made more available in health care settings would catch those flying under the radar.
“I think one of the problems that we have, especially as we move into influenza season, there’s the risk that, if you’re a physician, if they want to do influenza testing, they’re only really testing for the usual seasonal influenza, they’re not testing for [bird flu],” he said. “Otherwise, we’re never going to fully know the actual extent of the problem.”
Stockpiling bird flu vaccines
In early July, the U.S. government awarded Moderna $176 million to develop and test a bird flu vaccine using mRNA technology, which is the same technology used for the COVID vaccine.
In October, federal health officials announced they were providing $72 million to vaccine manufacturers to help ensure currently available bird flu vaccines are ready to use, if needed.
There are currently no recommendations for anyone in the U.S. to be vaccinated against bird flu, but experts say that could change if the virus becomes more transmissible.
Moody said clinical trials for new vaccines are being conducted and there are already bird flu vaccines in a stockpile maintained by the U.S. government that have previously been licensed by the FDA.
However, these three vaccines were formulated to protect against older strains of bird flu so there are questions about their protectiveness.
“One of the difficulties in making a stockpile is you’re trying to predict the future. Picking which influenza is going to be a problem is always the difficult bit,” Moody said. “So, I think that those vaccines that are in the stockpile, based on the data that I’ve seen, have a pretty good chance of being helpful. Whether or not they’ll be the answer that’s a that’s a tougher question to address.”
He said the U.S. is in a better position currently to address bird flu if it becomes an epidemic or pandemic than the country was to address COVID in 2020.
“We know how to do this. We know how to make these vaccines. We know how to get everything rolled out, and so I think we are in a better position today,” Moody said.
LW, who asked not to show her face, is a 16-year-old transgender teenager challenging Tennessee’s ban on gender-affirming medical treatments that have improved her quality of life. (ABC News)
(WASHINGTON) — Medical treatments for transgender children, endorsed by major American medical associations and safely used for decades, hang in the balance at the U.S. Supreme Court on Wednesday as the Biden administration and three families with transgender teenagers ask the justices to strike down a state law banning some gender-affirming care for kids.
The landmark case — U.S. v. Skrmetti — comes from Tennessee, which is among 26 states that have moved to prohibit administration of puberty-blocking medication and hormone therapy to minors who seek to identify with, or live as, a gender identity inconsistent with his or her sex at birth.
Oral arguments mark the first time the nation’s highest court has openly considered a state law targeting transgender people. It is also the first time an openly transgender litigator, ACLU attorney Chase Strangio, will argue a case in the Supreme Court chamber.
The historic hearing thrusts the justices to the forefront of a cultural debate that has sharply divided the country and tested the limits of science and parental rights.
The outcome of the case could determine access to health care for hundreds of thousands of trans teens and more broadly influence how communities treat transgender people in hospitals, schools and on sports fields.
The government argues that Tennessee’s SB1, which was enacted in March 2023, violates the Constitution’s Equal Protection clause because it discriminates on the basis of sex to decide who can receive otherwise legal medical treatments available to youth.
“Put simply, an adolescent assigned female at birth cannot receive puberty blockers or testosterone to live as a male, but an adolescent assigned male at birth can,” the administration wrote in its brief to the court.
The Tennessee law expressly allows minors who are not transgender to receive gender-affirming treatments to address a “congenital defect, precocious puberty, disease, or physical injury.”
Denying discrimination, the state argues its law is a reasonable regulation of medical treatment based on its purpose, meant to protect children from potential long-term health risks and possible irreversible changes to the body.
The law’s Republican sponsors claim that contradictory scientific evidence and documented regret among some young people who have transitioned both warrant caution in developing standards of care.
The law also cites a “compelling interest in encouraging minors to appreciate their sex, particularly as they undergo puberty” and preventing them from becoming “disdainful of their sex.” The government says the text proves an intent to enforce gender conformity.
Hundreds of Tennessee transgender children were receiving treatments before SB1 was enacted, legislators concluded. It is not known how many suffered alleged harm.
The plaintiffs in the case include 16-year-old LW and her parents Brian and Samantha Williams of Nashville. After several years of successful hormone therapy, LW now has to travel out of state to continue treatments she says have dramatically improved her quality of life.
“I feel normal now,” LW said in an exclusive interview with ABC News last month.
“Our state legislature had made such a big deal out of parents rights during COVID, about masks and vaccines — that that’s for parents to decide these medical decisions for their children,” noted Samantha Williams. “And then, they made this medical decision for our child.”
Nationwide, an estimated 300,000 Americans ages 13 to 17 identify as transgender, according to the Williams Institute at UCLA School of Law. Of those, nearly 100,000 live in states that have banned access to gender-affirming medical treatments for minors.
“It’s a case of enormous significance that presents fundamental questions about the scope of state power to regulate medical care for minors, of the rights of parents to make medical decisions for their children… and the level of scrutiny that courts should apply to laws that discriminate against transgender people in general,” said Deepak Gutpa, a veteran Supreme Court litigator. “This is a major, major constitutional civil rights issue.”
More than 60% of Americans say they oppose law banning certain types of gender-affirming medical treatment for minors, according to Gallup.
Major American medical associations have endorsed the treatments for more than a decade as part of “individually tailored interventions” to support trans kids and affirm their sense of self. Not all transgender children seek medical care to facilitate transition to another sex.
“It needs to be part of a very deliberate process that involves medical specialists, who are expert at doing this, and, again, are following the science,” said Dr. Ben Hoffman, a pediatrician and president of the American Academy of Pediatrics. “It all begins and ends with science. This is not about any sort of agenda.”
Clinical practice guidelines from the American Endocrine Society, based on more than 260 research studies, recommend the use of puberty-delaying medications and waiting until a child reaches adulthood to consider gender-affirming surgery.
The American Academy of Pediatrics says the effects of puberty blockers are not permanent if treatment is discontinued. Many effects of hormone therapy can also be reversed. Long-term risks may include fertility challenges and possible harm to bone density, but the group says those risks require further study.
In contrast to the U.S. medical establishment, several European countries, including the United Kingdom, have reversed course on the use of gender-affirming treatments as a standard-of-care for transgender children, citing insufficient scientific evidence of long-term benefits.
“When you look at the totality of the medical research, to me there is more than enough uncertainty and evidence of bad outcomes for kids who’ve gone through these treatments when they reach the later stages in life,” said Tennessee Senate GOP Leader Jack Johnson.
A federal district court sided with the plaintiffs, temporarily halting enforcement of SB1, but the Sixth Circuit U.S. Court of Appeals reversed. The panel of judges concluded Tennessee had a rational basis for enacting the law.
“Kind of the whole ballgame in the case is the debate about whether there actually is discrimination on the basis of sex,” said Erin Murphy, a Supreme Court litigator and former clerk to Chief Justice John Roberts.
“It’s really not,” Murphy argued. “To say providing testosterone to a biological boy and biological girl is the same thing because testosterone is involved — it’s a different treatment that has different risks.”
David Cole, former legal director of the American Civil Liberties Union, which is representing the Williams family, says the court’s conservative majority will have to confront the legacy of its decision.
“I think there’s no question in 25 years that the court will have recognized that treating people differently because their gender identity is sex discrimination,” Cole said.
“The question is whether the court wants to write a decision will be overturned, you know, in the course of the next 10 years or 15 years,” he said, “or whether it wants to recognize what is going on, which is sex discrimination.”
A decision in the case is expected by the end of June 2025.
